grant
Examining ketamine effects on depression, neuroplasticity, and inflammation in Veterans with Parkinson's disease
Organization VETERANS AFFAIRS MED CTR SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 1 Oct 2024Deadline 30 Sept 2029
VANIHUS FederalResearch GrantFY2025(TNF)-αAccelerationAcuteAddressAdverse ExperienceAdverse eventAfter CareAfter-TreatmentAftercareAnimal ModelAnimal Models and Related StudiesAnti-InflammatoriesAnti-Inflammatory AgentsAnti-inflammatoryAntiinflammatory EffectAreaAssayB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Stimulatory Factor-2BCDFBSF-2BSF2BehaviorBioassayBiological AssayBloodBlood Reticuloendothelial SystemBrainBrain Nervous SystemCNS plasticityCSIFCSIF-10CachectinCaringCausalityCell Death InductionClinicalClinical ResearchClinical StudyClinical TrialsClinical assessmentsCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalComplexCytokine Synthesis Inhibitory FactorDataDegenerative Neurologic DisordersDevelopmentDisablingDiseaseDisease ProgressionDisorderDisturbance in cognitionDoseDrug TherapyDysfunctionEmotional DepressionEncephalonEtiologyExposure toFrequenciesFunctional disorderFundingGlutamatesGoalsHPGFHepatocyte-Stimulating FactorHourHumanHybridoma Growth FactorIFN-GammaIFN-beta 2IFN-gIFN-γIFNB2IFNGIFNγIL-10IL-6IL10IL10AIL6 ProteinIV InfusionImmune InterferonImmune systemImpaired cognitionImpairmentInflammationInflammatoryInflammatory ResponseInfusionInfusion proceduresInterferon GammaInterferon Type IIInterleukin 10 PrecursorInterleukin-10Interleukin-6IntravenousIntravenous infusion proceduresInvestigatorsKetamineKnowledgeL-GlutamateLinkLong-Term PotentiationMGI-2Macrophage-Derived TNFMaintenanceMeasurementMeasuresMediatingMental DepressionMentorsMethodsMidazolamModern ManMonocyte-Derived TNFMontgomery and Asberg depression rating scaleMoodsMotor CortexMotor Evoked PotentialsMyeloid Differentiation-Inducing ProteinN-Methyl-D-Aspartate ReceptorsN-Methylaspartate ReceptorsNMDA Receptor-Ionophore ComplexNMDA ReceptorsNervous System Degenerative DiseasesNeural Degenerative DiseasesNeural degenerative DisordersNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsNeurologyNeuronal PlasticityNeurosciencesParalysis AgitansParkinsonParkinson DiseasePatientsPeripheralPharmacological TreatmentPharmacotherapyPhysiciansPhysiopathologyPlacebosPlasmacytoma Growth FactorPlayPopulationPrevalencePrimary ParkinsonismProcessPropertyProteinsPsychiatryPsychoneuroimmunologyPublishingQOLQuality of lifeRandomizedReceptor ActivationReportingResearch PersonnelResearchersRodentRodent ModelRodentiaRodents MammalsRoleSafetyScientistSerious Adverse EventSevere Adverse EventSeveritiesSham TreatmentSiteSynapsesSynapticSynaptic plasticityTNFTNF ATNF AlphaTNF geneTNF-αTNFATNFαTechniquesTestingTimeTrainingTranscranial magnetic stimulationTransmissionTumor Necrosis FactorTumor Necrosis Factor-alphaVeteransWorkantagonismantagonistanti-depressant agentanti-depressant drugsanti-depressant effectanti-depressantsanti-depressive agentsanti-inflammatory effectantidepressant effectcareercausationcentral nervous system plasticityclinical efficacycognitive dysfunctioncognitive losscytokinedegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdepressiondepression modeldepression symptomdepressivedepressive modeldepressive symptomsdesigndesigningdevelopmentaldisabilitydisabling symptomdisease causationdrug interventiondrug treatmenteffective therapyeffective treatmentexcitotoxicexcitotoxicityexperienceglutamate signalingglutamatergicglutamatergic dendrodendritic synapsesglutamatergic signalinghigh riskimmunogenicimprovedimproved outcomeindexinginfusionsinterferon beta 2intravenous infusionlFN-Gammamodel of animalmotor symptommulti-site trialmultiplex assaymultisite trialneural plasticityneurodegenerative illnessneuron toxicityneuronal toxicityneurophysiologicalneurophysiologyneuroplasticneuroplasticityneuroprotectionneuroprotectiveneuropsychiatricneuropsychiatric diseaseneuropsychiatric disorderneuropsychiatryneurotoxicitynew approachesnon-invasive brain stimulationnovelnovel approachesnovel strategiesnovel strategypathophysiologypharmaceutical interventionpharmacologicpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticspost treatmentpre-clinicalpre-clinical studypreclinicalpreclinical studyprimary end pointprimary endpointprogramspsychoneuroimmunologicalrandomisationrandomizationrandomized placebo controlled studyrandomly assignedsecondary end pointsecondary endpointserious adverse experienceserious adverse reactionsham therapyside effectskillssocial rolestemstressorsuicidal risksuicide risksynapsesystemic inflammationsystemic inflammatory responsetransmission process
Description preview
Parkinson’s disease (PD) is a complex, disabling neuropsychiatric disorder with growing impact on Veterans in
terms of prevalence and disability. Depression in PD (dPD) is common, a stronger predictor of quality of life
than the hallmark motor symptoms of the illness, and associated with accelerated decline and elevated risk of
suicide.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click